Enkephalinase inhibitors, potential therapeutics for the future treatment of diarrhea predominant functional gastrointestinal disorders.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Enkephalinase inhibitors, potential therapeutics for the future treatment of diarrhea predominant functional gastrointestinal disorders.
- Published In:
- Neurogastroenterology and motility, 31(4), e13526 (2019)
- Database ID:
- RPEP-04501
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-04501APA
Szymaszkiewicz, Agata; Storr, Martin; Fichna, Jakub; Zielinska, Marta. (2019). Enkephalinase inhibitors, potential therapeutics for the future treatment of diarrhea predominant functional gastrointestinal disorders.. Neurogastroenterology and motility, 31(4), e13526. https://doi.org/10.1111/nmo.13526
MLA
Szymaszkiewicz, Agata, et al. "Enkephalinase inhibitors, potential therapeutics for the future treatment of diarrhea predominant functional gastrointestinal disorders.." Neurogastroenterology and motility, 2019. https://doi.org/10.1111/nmo.13526
RethinkPeptides
RethinkPeptides Research Database. "Enkephalinase inhibitors, potential therapeutics for the fut..." RPEP-04501. Retrieved from https://rethinkpeptides.com/research/szymaszkiewicz-2019-enkephalinase-inhibitors-potential-therapeutics
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.